Cannara Biotech Inc. (LOVE) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Welcome to Canara Biotech's Q2 2026 earnings call for the three months ended February 28th, 2026. Today's presenter is Nicholas Sosiak, CFO, joined by Zohar Kriberat, founder and CEO. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephones. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. Before we begin, please refer to slide two and three for our caution regarding forward-looking statements and non-GAAP measures. I will now turn the call over to Nicholas. You may begin. Good morning, everyone, and thank you for joining our Q2 earnings call. Q2 reflects continued execution of a model that is delivering consistent and profitable growth. For the quarter, Canara delivered 27.2 million in revenue with strong margins and profitability, generating 6 million of adjusted EBITDA and 2.9 million of operating cash flow. This represents our 20th consecutive quarter of positive adjusted EBITDA and our 14th consecutive quarter of positive operating cash flow. Despite normal seasonality, we outperformed the market, increasing retail sales and expanding market share while maintaining profitability. We increased national retail market share to 4.4% and defended our position as the number one licensed producer in Quebec, achieved in December of 2025. This performance reflects a system that is working. Our model is built on delivering premium quality cannabis at competitive price points, supported by a structurally low-cost, vertically integrated platform....